27-Sep-2024
Clover Health names Joseph Brand as COO for Medicare Advantage
Seeking Alpha News (Thu, 26-Sep 4:12 PM ET)
Globe Newswire (Thu, 26-Sep 4:00 PM ET)
Globe Newswire (Tue, 3-Sep 4:05 PM ET)
Globe Newswire (Thu, 22-Aug 9:00 AM ET)
Clover Health to Participate in Upcoming 2024 Wells Fargo Healthcare Conference
Globe Newswire (Wed, 21-Aug 4:05 PM ET)
Globe Newswire (Mon, 5-Aug 4:05 PM ET)
Globe Newswire (Wed, 24-Jul 4:05 PM ET)
Clover Health to Report Second Quarter 2024 Financial Results on August 5
Globe Newswire (Mon, 22-Jul 4:05 PM ET)
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. Operating in two segments, Insurance and Non-Insurance, Clover Health offers PPO and HMO plans to Medicare Advantage members in multiple states through its Insurance segment. In the Non-Insurance segment, the company participates in the ACO REACH Model. The majority of revenue is generated from the insurance segment, reflecting the significance of its healthcare insurance offerings.
Clover Health Investments Corp. - Class A trades on the NASDAQ stock market under the symbol CLOV.
As of September 27, 2024, CLOV stock price declined to $2.82 with 3,118,953 million shares trading.
CLOV has a beta of 2.72, meaning it tends to be more sensitive to market movements. CLOV has a correlation of 0.23 to the broad based SPY ETF.
CLOV has a market cap of $1.40 billion. This is considered a Small Cap stock.
Last quarter Clover Health Investments Corp. - Class A reported $356 million in Revenue and $.01 earnings per share. This beat revenue expectation by $18 million and exceeded earnings estimates by $.06.
In the last 3 years, CLOV traded as high as $8.58 and as low as $.61.
The top ETF exchange traded funds that CLOV belongs to (by Net Assets): VTI, VXF, SCHA, PRFZ, VHT.
CLOV has outperformed the market in the last year with a return of +151.8%, while the SPY ETF gained +35.8%. In the last 3 month period, CLOV beat the market returning +120.3%, while SPY returned +5.1%. However, in the most recent 2 weeks CLOV has underperformed the stock market by returning +1.8%, while SPY returned +2.5%.
CLOV support price is $2.72 and resistance is $3.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLOV shares will trade within this expected range on the day.